Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

20122,786 citationsJournal Articlebronze Open Access

Authors

Keith T. Flaherty · Massachusetts General Hospital

J. Infante · Tennessee Oncology

Adil Daud · University of California, San Francisco

René González · University of Colorado Cancer Center

Richard Kefford · The University of Sydney

Jeffrey A. Sosman · Vanderbilt University

Omid Hamid

Abstract

Dabrafenib and trametinib were safely combined at full monotherapy doses. The rate of pyrexia was increased with combination therapy, whereas the rate of proliferative skin lesions was nonsignificantly reduced. Progression-free survival was significantly improved. (Funded by GlaxoSmithKline; ClinicalTrials.gov number, NCT01072175.).

Topics & Keywords

Melanoma and MAPK Pathways Cytokine Signaling Pathways and Interactions HER2/EGFR in Cancer Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 367, Issue 18, pp. 1694-1703

DOI: 10.1056/nejmoa1210093

Field-Weighted Citation Impact: 141.50